CA Patent

CA3016876C — Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones

Assigned to IO Therapeutics Inc · Expires 2021-12-28 · 4y expired

What this patent protects

Improvement of the efficacy of Retinoic X Receptor (RXR) agonists in autoimmune diseases is needed. The present specification describes the use of a combination of a RXR agonist and a thyroid hormone for treating autoimmune diseases more effectively than use of either the RXR ago…

USPTO Abstract

Improvement of the efficacy of Retinoic X Receptor (RXR) agonists in autoimmune diseases is needed. The present specification describes the use of a combination of a RXR agonist and a thyroid hormone for treating autoimmune diseases more effectively than use of either the RXR agonist or the thyroid hormone alone. The described RXR agonists have the structure of Formula II: (see formula II) wherein R is H or lower alkyl of 1 to 6 carbons.

Drugs covered by this patent

Patent Metadata

Patent number
CA3016876C
Jurisdiction
CA
Classification
—
Expires
2021-12-28
Drug substance claim
No
Drug product claim
No
Assignee
IO Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.